The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) hit a new 52-week low and has $15.27 target or 7.00% below today’s $16.42 share price. The 6 months bearish chart indicates high risk for the $980.31M company. The 1-year low was reported on Nov, 8 by Barchart.com. If the $15.27 price target is reached, the company will be worth $68.62M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 556,431 shares traded hands. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has declined 21.49% since April 5, 2016 and is downtrending. It has underperformed by 23.44% the S&P500.
Analysts await Portola Pharmaceuticals Inc (NASDAQ:PTLA) to report earnings on November, 14. They expect $-1.11 earnings per share, down 5.71% or $0.06 from last year’s $-1.05 per share. After $-1.02 actual earnings per share reported by Portola Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 8.82% negative EPS growth.
Portola Pharmaceuticals Inc (NASDAQ:PTLA) Ratings Coverage
Out of 4 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 1 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 25% are positive. Portola Pharmaceuticals has been the topic of 11 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) earned “Buy” rating by Goldman Sachs on Friday, December 18. The firm has “Buy” rating by Citigroup given on Wednesday, August 10. Citigroup maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) on Friday, May 27 with “Buy” rating. Credit Suisse maintained Portola Pharmaceuticals Inc (NASDAQ:PTLA) rating on Monday, March 28. Credit Suisse has “Outperform” rating and $34 price target. The company was downgraded on Tuesday, May 31 by Credit Suisse. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) earned “Neutral” rating by Credit Suisse on Friday, August 19. The firm earned “Overweight” rating on Friday, August 19 by Morgan Stanley. The firm has “Neutral” rating given on Monday, March 28 by Goldman Sachs. The stock has “Neutral” rating given by Citigroup on Friday, August 19. The firm has “Buy” rating given on Wednesday, August 5 by Cowen & Co.
According to Zacks Investment Research, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.”
Insitutional Activity: The institutional sentiment increased to 1.09 in Q2 2016. Its up 0.03, from 1.06 in 2016Q1. The ratio is positive, as 26 funds sold all Portola Pharmaceuticals Inc shares owned while 43 reduced positions. 16 funds bought stakes while 59 increased positions. They now own 51.75 million shares or 1.93% less from 52.77 million shares in 2016Q1.
Emerald Advisers Pa holds 0.73% or 640,444 shares in its portfolio. Balyasny Asset Mngmt Limited Company holds 388,026 shares or 0.06% of its portfolio. Price T Rowe Associate Md last reported 0% of its portfolio in the stock. Jacobs Levy Equity Inc has 137,830 shares for 0.07% of their US portfolio. Oxford Asset Mngmt holds 0.19% or 197,199 shares in its portfolio. Glenmede Tru Co Na last reported 1,000 shares in the company. Redmile Grp Limited Liability Com last reported 3.31% of its portfolio in the stock. First Personal Ser accumulated 427 shares or 0% of the stock. Harvey Cap has 2.44% invested in the company for 206,530 shares. Bnp Paribas Arbitrage Sa reported 1,954 shares or 0% of all its holdings. Quantbot Technology Limited Partnership reported 1,507 shares or 0% of all its holdings. Swiss Comml Bank owns 92,057 shares or 0% of their US portfolio. Jane Street Gp Limited Co reported 11,853 shares or 0% of all its holdings. Grp One Trading L P owns 5,882 shares or 0% of their US portfolio. Fernwood Ltd Llc owns 232,952 shares or 5.39% of their US portfolio.
More notable recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Seekingalpha.com which released: “Portola Pharmaceuticals’ (PTLA) CEO Bill Lis on Q3 2016 Results – Earnings …” on November 08, 2016, also Fool.com with their article: “Why Portola Pharmaceuticals Inc Is Plunging Today” published on August 18, 2016, Fool.com published: “Why Portola Pharmaceuticals, Inc. Increased 11.6% in April” on May 11, 2016. More interesting news about Portola Pharmaceuticals Inc (NASDAQ:PTLA) were released by: Fool.com and their article: “Why Portola Pharmaceuticals Inc’s Stock Is Bleeding Red Today” published on March 24, 2016 as well as Fool.com‘s news article titled: “Portola Pharmaceuticals: Does New Data Get It Back on Track?” with publication date: May 28, 2016.
PTLA Company Profile
Portola Pharmaceuticals, Inc., incorporated on September 2, 2003, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. The Company’s third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Firm has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.